~~<i id='20F82903B4'><strike id='20F82903B4'><tt id='20F82903B4'><pre id='20F82903B4'></pre></tt></strike></i>~~

Home» explore» hotspot

hotspot

author：leisure time 2025-09-28 20:02:31 Page View：73272

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Kremlin open to talks over potential prisoner swap involving detained US reporter Evan Gershkovich
Next article： Medical leaders decry Supreme Court decision on affirmative action

explore

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

Brazil's Neymar fined $3.3 million for illegal artificial lake at mansion outside Rio

BraziliansoccerplayerNeymarwatchesduringthefirsthalfofGame4ofthebasketballNBAFinalsbetweentheMiamiHe

Dobbs anniversary: the lost opportunity of abortion as health care

NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

3 killed, 8 injured in late

11:16STOCKPHOTO/GettyImagesAtleastthreepeoplewerekilledandeightotherswereinjuredinashootinglateMonda